Evidence map›Paper›PMID 32366738›Full record

ArticleJournal of genetics2020

Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer.

Asuman Özgöz, Fadİme Mutlu İçduygu, Ayşegül Yükseltürk, Hale ŞamlI, Kuyaş Hekİmler Öztürk, Zuhal Başkan

Abstract read
PubMed
In one paragraph

Article in Journal of genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Update on the relationship between theThe Journal of international medical research · 2023
    Pooled it
  2. LowerBiology · 2024
    Article
  3. International journal of molecular sciences · 2024
    Article
  4. FGFR2 genetic variants in women with breast cancer.Molecular medicine reports · 2023
    Article
  5. Risk Association ofCurrent oncology (Toronto, Ont.) · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Asuman ÖzgözKastamonu School of Medicine, Department of Medical Genetics, Kastamonu University, Kastamonu 37200, Turkey. biologistasu@gmail.com.
Fadİme Mutlu İçduygu
Ayşegül Yükseltürk
Hale ŞamlI
Kuyaş Hekİmler Öztürk
Zuhal Başkan
Kastamonu University · TRAcıbadem Adana Hospital · TRBursa Uludağ Üni̇versi̇tesi̇ · TRGiresun University · TRSüleyman Demirel University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk of breast cancer (BC) in women is high and many factors including genetic factors increase the risk for the disease. It is revealed that the variations of low-penetrance susceptibility genes are important for carcinogenesis as they interact with the environmental and hereditary factors. Recently, the list of BC-associated common single nucleotide polymorphisms (SNPs) and chromosomal loci in low-penetrance susceptibility genes have been expanded in genomewide association studies. FGFR2, LSP1, MAP3K1, TGFB1, TOX3, 2q35 and 8q loci variations are some examples for these common SNPs. These SNPs and their association with BC risk was investigated in many different populations. Therefore in this study, we aimed to evaluate low-penetrance susceptibility SNPs; namely FGFR2 rs1219648, rs2981579, rs2981582; MAP3K1 rs889312; TOX3 rs3803662; LSP1 rs909116, rs3817198 and SLC4A7 rs4973768 together, for the firsttime in Turkish postmenopausal oestrogen receptor positive BC cases. Following the DNA isolation, multiplex PCR and matrix-assisted laser desorption/ionization mass spectrometry with time of flight measurement (MALDI-TOF) based SNP analysis were performed. MAP3K1 rs889312 SNP demonstrated the strongest association with BC risk among the other low penetrant SNPs, it was also associated with BC risk in a dominant model. Only in a ressesive model, TOX3 rs3803662 was associated with BC risk. In addition, rs4973768 CC and rs909116 CC genotypes are correlated with higher tumour size which is not reported in the literature as yet; on the other hand there are no associations between any of the other SNP genotypes and clinopathological parameters. In our opinion, MAP3K1 rs889312 may be a good BC susceptibility biomarker candidate for Turkish population.

Indexed as

PenetrancePolymorphism, Single NucleotideAgedAllelesApoptosis Regulatory ProteinsBreast NeoplasmsCase-Control StudiesFemaleGenetic MarkersGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMAP Kinase Kinase Kinase 1Microfilament ProteinsMiddle AgedApoptosis Regulatory ProteinsFGFR2 protein, humanGenetic MarkersLSP1 protein, humanMAP3K1 protein, humanMAP Kinase Kinase Kinase 1Microfilament ProteinsReceptor, Fibroblast Growth Factor, Type 2Receptors, EstrogenSLC4A7 protein, humanSodium-Bicarbonate SymportersTOX3 protein, humanTrans-Activators

Identifiers

PMID32366738
OpenAlexW3027095938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.